Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin

Andrew F. Shorr, Gregory M. Susla, Marin H. Kollef

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

Objectives: To determine the incremental cost-effectiveness of linezolid compared with vancomycin for treatment of ventilator-associated pneumonia due to Staphylococcus aureus. Design: Decision model analysis of the cost and efficacy of linezolid vs. vancomycin for treatment of ventilator-associated pneumonia. The primary outcome was the incremental cost-effectiveness of linezolid in terms of cost per added quality-adjusted life-year gained. Other outcomes were the marginal costs per hospital survivor and per year of life saved generated by using linezolid. Model estimates were derived from prospective trials of linezolid for ventilator-associated pneumonia and from other studies describing the costs and outcomes for ventilator-associated pneumonia. Setting and Patients: Hypothetical cohort of 1,000 patients diagnosed with ventilator-associated pneumonia. Interventions: In the model, patients received either linezolid or vancomycin. Measurements and Main Results: The incremental cost-effectiveness of linezolid was calculated as the additional quality-adjusted life-years resulting from therapy with linezolid divided by the sum of the incremental costs arising because of use of linezolid (e.g., higher direct costs for linezolid, costs per in-hospital care of survivors, and posthospitalization costs). Despite its higher cost, linezolid was cost-effective for treatment of ventilator-associated pneumonia. The cost per quality-adjusted life-year equals approximately $30,000. The model was moderately sensitive to the estimated efficacy of linezolid over vancomycin. Nonetheless, even with all inputs simultaneously skewed against, linezolid remains a cost-effective option (cost per quality-adjusted life-year approximately $100,000). Based on Monte Carlo simulation, the results of our analysis are robust across a range of model inputs and assumptions (95% confidence interval for cost per quality-adjusted life-year ranges from $23,637 to $42,785). Conclusions: Linezolid is a cost-effective alternative to vancomycin for the treatment of ventilator-associated pneumonia.

Original languageEnglish
Pages (from-to)137-143
Number of pages7
JournalCritical care medicine
Volume32
Issue number1
DOIs
StatePublished - Jan 2004

Keywords

  • Cost
  • Cost-effectiveness
  • Gram-positive
  • Linezolid
  • Pneumonia
  • Vancomycin
  • Ventilator

Fingerprint Dive into the research topics of 'Linezolid for treatment of ventilator-associated pneumonia: A cost-effective alternative to vancomycin'. Together they form a unique fingerprint.

  • Cite this